Pfizer seeks label expansion for Litfulo after double Phase III NSV win

Phase 3positiveLitfuloPositive

AI Analysis

Summary

Pfizer's Litfulo achieved positive Phase III results in the TRANQUILLO programme for non-scarring alopecia (NSV), positioning the drug for potential label expansion. The drug is already approved in alopecia areata.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Double Phase III NSV win in TRANQUILLO programme

Importance:7/10

Sentiment:

0.80

label expansionalopeciaPhase 3 successnon-scarring alopeciaTRANQUILLO

Related Companies

$PFE

Read the original article

Published by Pharmaceutical Technology on July 30, 2026 3:33 PM

Read Original